Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Caribou Biosciences Inc (CRBU)

Caribou Biosciences Inc (CRBU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Caribou Biosciences Inc 2929 7TH STREET SUITE 105 BERKELEY CA 94710 USA

www.cariboubio.com Employees: 147 P: 510-982-6030

Sector:

Medical

Description:

Caribou Biosciences Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company. It involved in developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. Caribou Biosciences Inc. is based in BERKELEY, Calif.

Key Statistics

Overview:

Market Capitalization, $K 173,850
Enterprise Value, $K 157,560
Shares Outstanding, K 93,468
Annual Sales, $ 9,990 K
Annual Net Income, $ -149,110 K
Last Quarter Sales, $ 2,200 K
Last Quarter Net Income, $ -27,550 K
EBIT, $ -158,770 K
EBITDA, $ -159,570 K
60-Month Beta 2.60
% of Insider Shareholders 8.28%
% of Institutional Shareholders 77.51%
Float, K 85,729
% Float 91.72%
Short Volume Ratio 0.52

Growth:

1-Year Return -4.67%
3-Year Return -78.37%
5-Year Return 0.00%
5-Year Revenue Growth 72.54%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.30 on 11/12/25
Next Earnings Date N/A
Earnings Per Share ttm -1.47
EPS Growth vs. Prev Qtr 14.29%
EPS Growth vs. Prev Year 21.05%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

CRBU Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -69.85%
Return-on-Assets % -54.20%
Profit Margin % -1,492.59%
Debt/Equity 0.00
Price/Sales 16.46
Price/Cash Flow N/A
Price/Book 1.16
Book Value/Share 1.52
Interest Coverage -2.21
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar